| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA4059998
Max Phase: Preclinical
Molecular Formula: C70H111BrN22O16
Molecular Weight: 1596.70
Molecule Type: Small molecule
Associated Items:
Representations
Canonical SMILES: CCCC[C@H](NC(=O)[C@@H]1CCCN1C(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H]1CCC(=O)N1)C(=O)NC(C)(C)C(=O)N[C@@H](Cc1ccc(Br)cc1)C(=O)O
Standard InChI: InChI=1S/C70H111BrN22O16/c1-7-8-15-44(60(101)90-70(4,5)67(109)89-49(66(107)108)33-40-21-23-41(71)24-22-40)84-61(102)51-19-13-30-92(51)55(96)36-80-56(97)43(16-9-10-27-72)83-58(99)48(34-42-35-77-38-81-42)87-59(100)50(37-94)88-63(104)53(32-39(2)3)91(6)64(105)46(17-11-28-78-68(73)74)86-62(103)52-20-14-31-93(52)65(106)47(18-12-29-79-69(75)76)85-57(98)45-25-26-54(95)82-45/h21-24,35,38-39,43-53,94H,7-20,25-34,36-37,72H2,1-6H3,(H,77,81)(H,80,97)(H,82,95)(H,83,99)(H,84,102)(H,85,98)(H,86,103)(H,87,100)(H,88,104)(H,89,109)(H,90,101)(H,107,108)(H4,73,74,78)(H4,75,76,79)/t43-,44-,45-,46-,47-,48-,49-,50-,51-,52-,53-/m0/s1
Standard InChI Key: HLQNQERXFGPNSD-ZOOWYRFPSA-N
Associated Targets(Human)
MME Tclin Neprilysin (838 Activities)
APLNR Tchem Apelin receptor (3301 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Associated Targets(non-human)
Aplnr Apelin receptor (201 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Mus musculus (284745 Activities)
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 1596.70 | Molecular Weight (Monoisotopic): 1594.7732 | AlogP: | #Rotatable Bonds: |
| Polar Surface Area: | Molecular Species: | HBA: | HBD: |
| #RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
| CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
| Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
References
| 1. McKinnie SMK, Wang W, Fischer C, McDonald T, Kalin KR, Iturrioz X, Llorens-Cortes C, Oudit GY, Vederas JC.. (2017) Synthetic Modification within the "RPRL" Region of Apelin Peptides: Impact on Cardiovascular Activity and Stability to Neprilysin and Plasma Degradation., 60 (14): [PMID:28685579] [10.1021/acs.jmedchem.7b00723] |
| 2. Fernandez KX, Fischer C, Vu J, Gheblawi M, Wang W, Gottschalk S, Iturrioz X, Llorens-Cortés C, Oudit GY, Vederas JC.. (2021) Metabolically stable apelin-analogues, incorporating cyclohexylalanine and homoarginine, as potent apelin receptor activators., 12 (8.0): [PMID:34458742] [10.1039/D1MD00120E] |
Source
Source(1):